Natco Pharma posts over six-fold jump in consolidated net profit to Rs 369 crore in Q2
Hyderabad: Natco Pharma has reported an over six-fold jump in its consolidated net profit to Rs 369 crore in the second quarter ended September 30, 2023.The Hyderabad-based drug firm had reported a net profit of Rs 57 crore in the July-September period of last fiscal.Consolidated total revenue rose to Rs 1,061 crore for the period under review, as compared with Rs 453 crore in the...
Hyderabad: Natco Pharma has reported an over six-fold jump in its consolidated net profit to Rs 369 crore in the second quarter ended September 30, 2023.
Read also: Natco Pharma net profit rises 31.2 percent to Rs 420.3 crore in Q1
Natco Pharma Limited is a vertically integrated and R&D focused pharmaceutical company engaged in developing, manufacturing and marketing of finished dosage formulations (“FDF”) and active pharmaceutical ingredients (“APIs”). The company's focus is primarily on niche therapeutic areas and complex products. It markets and distributes products in over 40 countries. It sells FDF products in the United States, India, Europe and the rest of the world (“RoW”). Natco also operates in certain key geographies through its subsidiaries.
Natco Pharma is also engaged in contract manufacturing business, whereby it undertakes selected contracts with pharmaceutical companies to manufacture and supply pharmaceutical products.
Read also: Natco Pharma Pharmacovigilance department successfully completes USFDA inspection
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd